Beyond Detection: How DNA is Redefining the Fight Against Glaucoma

SAN DIEGO, CA – November 13, 2026

For decades, the battle against glaucoma has been fought in the dark. Dubbed the "silent thief of sight," the disease strips away peripheral vision so gradually that patients often remain unaware until the damage is irreversible. Traditional clinical tools—intraocular pressure (IOP) tonometers, visual field tests, and optic nerve imaging—have historically served as the primary line of defense. Yet, these methods frequently detect the disease only after significant retinal nerve fiber loss has already occurred.

Now, the frontier of ophthalmic care is shifting from reactive detection to predictive genomics. Seonix Bio, a San Diego-based diagnostic developer, has released new peer-reviewed research in Ophthalmology validating the polygenic risk score (PRS) underlying its SightScore test. The findings suggest that a simple saliva test can not only identify individuals at high risk for glaucoma but also predict disease progression and the likelihood of future surgical intervention.

As the medical community gathers this week for the Interventional Glaucoma Consortium in Salt Lake City, the intersection of genetic data and clinical ophthalmology is poised to fundamentally disrupt how specialists triage, monitor, and treat one of the world's leading causes of irreversible blindness.

From Simple Screening to Surgical Prognosis

The sheer scale of the data behind the recent publication is staggering. Leveraging genetic information from more than 6.5 million individuals, researchers evaluated the PRS across independent cohorts to stratify patients by their inherent susceptibility to the disease.

The statistical divergence between risk groups is profound. According to the study, individuals in the highest 10 percent of genetic risk exhibit approximately 100 times the odds of developing glaucoma compared to those in the lowest decile. On a population level, this high-risk group reaches a 3 percent disease prevalence more than 25 years earlier than their low-risk counterparts.

However, the most disruptive element of the research lies not in mere susceptibility, but in prognosis. In a prospective longitudinal cohort of 1,215 participants with suspected or early-stage glaucoma, 24 percent of those in the highest PRS decile required glaucoma surgery by age 80. In stark contrast, none of the patients in the lowest decile required surgical intervention. Higher scores were also directly correlated with accelerated retinal nerve fiber layer loss and a faster escalation of treatment within three years.

“Glaucoma care has traditionally relied on clinical measurements that may not fully capture a patient’s inherited risk or predict future disease course,” said Nick Haan, CEO of Seonix Bio. “This research shows the potential of genetic information to add a meaningful dimension to risk assessment, not only helping identify who may develop glaucoma, but also providing insight into who may be more likely to progress and require surgery.”

Iqbal “Ike” K. Ahmed, MD, FRCSC, Professor of Ophthalmology at the University of Utah’s John A. Moran Eye Center, echoed this sentiment. “A persistent challenge in glaucoma is determining which patients are most likely to progress and may benefit from intervention. These findings are notable because they connect genetic risk not only with disease susceptibility, but also with progression and the likelihood of surgery.”

Bridging the Ancestral Data Gap

A persistent criticism of genomic medicine has been its historical reliance on biobanks overwhelmingly populated by individuals of European descent. This systemic bias often results in polygenic risk scores that perform poorly—or even misleadingly—when applied to minority populations.

For glaucoma, a disease characterized by severe health disparities, this data gap is particularly dangerous. African American and Latino populations face a disproportionately high burden of the disease, often experiencing earlier onset and more aggressive progression leading to blindness.

The Ophthalmology publication directly addresses this vulnerability. The study demonstrates that the underlying PRS maintains predictive value across European, African, East Asian, South Asian, and Latino ancestry groups. In a specific U.S. African American cohort, those in the highest-risk 10 percent had nearly four times the odds of developing glaucoma compared to the rest of the cohort.

Independent clinical geneticists note that while predictive accuracy may still lean slightly toward European cohorts due to the sheer volume of legacy data, achieving validated, cross-ancestry predictive power is a critical milestone for health equity. By adding PRS to standard models that include age, sex, and eye pressure, clinicians can drastically improve prediction models for minority cohorts, potentially catching aggressive cases years before traditional clinical signs manifest.

Navigating the Commercial and Clinical Labyrinth

Despite the robust scientific validation, the transition from an academic breakthrough—originally pioneered by Australia's QIMR Berghofer and Flinders University—to a commercially viable, widely adopted clinical tool is fraught with hurdles.

The regulatory landscape for diagnostics is currently in a state of flux. Tests like SightScore typically enter the market as Laboratory Developed Tests (LDTs) under Clinical Laboratory Improvement Amendments (CLIA) certification, a faster route than the traditional FDA pre-market approval process. However, federal regulators have recently signaled strong intentions to phase out enforcement discretion for LDTs, which could subject diagnostic developers to a more rigorous, time-consuming, and expensive compliance environment.

Beyond regulation, the ultimate gatekeepers of commercial success are insurers and Medicare. The Centers for Medicare & Medicaid Services (CMS) and private payers demand incontrovertible evidence of "clinical utility." It is not enough for a test to be accurate; it must demonstrably alter clinical decision-making in a way that improves patient outcomes and, ideally, reduces systemic healthcare costs.

Health economists point out that routine genetic screening for asymptomatic individuals faces intense payer scrutiny. The company will need to mount extensive health economics and outcomes research (HEOR) to prove that the upfront cost of DNA testing prevents the massive downstream expenditures associated with advanced glaucoma, such as complex surgeries and the societal costs of blindness.

Furthermore, there is the challenge of clinical integration. Busy ophthalmology practices require clear, actionable guidelines. If a patient presents with normal eye pressure but a high genetic risk score, medical societies like the American Academy of Ophthalmology will need to establish consensus on whether to initiate prophylactic treatment or simply increase surveillance frequency. Conversely, there is the psychological risk of false reassurance; patients with low genetic risk scores must still be educated that environmental factors and aging can trigger the disease, meaning routine eye exams cannot be entirely abandoned.

These operational and economic questions will take center stage as the industry looks toward the Interventional Glaucoma Consortium this week. On November 14, Dr. Jamie E. Craig, Professor of Ophthalmology at Flinders University and a key architect of the PRS technology, will deliver a keynote address detailing how polygenic risk can guide interventional approaches, signaling the next critical phase in bringing genomic foresight into the everyday clinic.